Insider

Thermo Fisher Scientific Inc.

TMO Health Care · 2 analyses

Thermo Fisher Scientific reported $12.1B in revenue (+9.1% YoY), compared with a +7.2% median across covered Health Care peers. 2 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Company history

October 2026

THERMO FISHER SCIENTIFIC INC.: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-06-28 to 2026-09-26: 12,137,000,000 USD (12.1 billion; 12,137 million); same period a year earlier (2025-06-29 to 2025-09-27): 11,122,000,000 USD (11.1 billion; 11,122 million); change +9.1% Source
  • 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-26: 35,136,000,000 USD (35.1 billion; 35,136 million); same period a year earlier (2025-01-01 to 2025-09-27): 32,341,000,000 USD (32.3 billion; 32,341 million); change +8.6% Source
  • 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-06-28 to 2026-09-26: 2,263,000,000 USD (2.3 billion; 2,263 million); same period a year earlier (2025-06-29 to 2025-09-27): 1,941,000,000 USD (1.9 billion; 1,941 million); change +16.6% Source
  • 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-26: 6,213,000,000 USD (6.2 billion; 6,213 million); same period a year earlier (2025-01-01 to 2025-09-27): 5,491,000,000 USD (5.5 billion; 5,491 million); change +13.1% Source
  • 2026-10-30: Net income (us-gaap:NetIncomeLoss), quarter 2026-06-28 to 2026-09-26: 1,721,000,000 USD (1.7 billion; 1,721 million); same period a year earlier (2025-06-29 to 2025-09-27): 1,616,000,000 USD (1.6 billion; 1,616 million); change +6.5% Source
  • 2026-10-30: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-26: 5,108,000,000 USD (5.1 billion; 5,108 million); same period a year earlier (2025-01-01 to 2025-09-27): 4,740,000,000 USD (4.7 billion; 4,740 million); change +7.8% Source
  • 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-06-28 to 2026-09-26: 348,000,000 USD (348 million); same period a year earlier (2025-06-29 to 2025-09-27): 346,000,000 USD (346 million); change +0.6% Source
  • 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-26: 1,048,000,000 USD (1 billion; 1,048 million); same period a year earlier (2025-01-01 to 2025-09-27): 1,041,000,000 USD (1 billion; 1,041 million); change +0.7% Source
  • 2026-10-30: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-26: 5,867,000,000 USD (5.9 billion; 5,867 million); same period a year earlier (2025-01-01 to 2025-09-27): 4,361,000,000 USD (4.4 billion; 4,361 million); change +34.5% Source
  • 2026-10-30: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-26: 1,263,000,000 USD (1.3 billion; 1,263 million); same period a year earlier (2025-01-01 to 2025-09-27): 1,060,000,000 USD (1.1 billion; 1,060 million); change +19.2% Source
  • 2026-10-30: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-26: 5,461,000,000 USD (5.5 billion; 5,461 million); previous balance (2025-12-31): 9,852,000,000 USD (9.9 billion; 9,852 million); change -44.6% Source
  • 2026-10-30: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-26: 54,761,000,000 USD (54.8 billion; 54,761 million); previous balance (2025-12-31): 53,407,000,000 USD (53.4 billion; 53,407 million); change +2.5% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 26, 2026, filed October 30, 2026. SEC

LatestEarlierChange
Revenue quarter$12.1B$11.1B+9.1%
Operating income quarter$2.3B$1.9B+16.6%
Net income quarter$1.7B$1.6B+6.5%
Diluted EPS quarter$4.64$4.27+8.7%
Dividends per share quarter$0.47$0.43+9.3%
Operating cash flow year to date$5.9B$4.4B+34.5%
Cash and cash equivalents balance$5.5B$9.9B-44.6%
Long-term debt balance$41.1B$39.2B+4.9%

Next results expected around January 29, 2027 (estimate: the quarter ending about December 26, 2026 plus the 34 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

11.4Q4 '24*17.7%10.4Q1 '2516.6%10.9Q2 '2516.9%11.1Q3 '2517.5%12.2Q4 '25*18.5%11Q1 '2616.9%12Q2 '2617.4%12.1Q3 '2618.6%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Thermo Fisher Scientific Inc. TMO$12.1B+9.1%18.6%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 30, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 13, 2026Gianluca PettitiSale 10b5-1 plan notice filed4,133$701.42$2,898,969SEC
October 28, 2026Lisa P. BrittSale notice filed2,831$706.45$1,999,960SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock32,167,485$21,714,660,329+4.0%Q3 2026
Fidelity (FMR)22,173,792$14,968,417,646+57.4%Q3 2026
State Street16,892,592$11,411,187,757+0.4%Q3 2026
Geode Capital Management8,462,804$5,686,031,476+1.0%Q3 2026
Capital Research Global Investors4,188,289$2,827,348,657+1.0%Q3 2026
Norges Bank (Norway's sovereign fund)5,087,903$2,550,871,048—Q2 2026
Wellington Management788,510$532,283,677-19.5%Q3 2026
D. E. Shaw & Co.172,575$116,496,753-73.1%Q3 2026
Bridgewater Associates154,647$104,394,457+1,094.4%Q3 2026
Citadel Advisors149,695$101,051,610-74.0%Q3 2026
Millennium Management134,801$90,997,415-18.5%Q3 2026
Renaissance Technologies138,964$68,304,975—Q1 2026
Two Sigma Investments16,994$11,471,800-0.1%Q3 2026
T. Rowe Price6,299,749$4,252,647+23.1%Q3 2026
Duquesne Family Office (Stanley Druckenmiller)19,200$9,626—Q2 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.